Position in URGN
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$8,990,000
-$2,720,000 QoQ
Shares Held
500,000
0.0% QoQ
Ownership
1.03%
of shares outstanding
% of Portfolio
1.19%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2025
4 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in URGN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Boxer Capital Management, LLC holds $739,844,214 across 50 Biotechnology names. URGN ranks #21 (1.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | TNGX |
Tango Therapeutics, Inc.
|
10,876,219 | $227,530,501 | |
| 2 | KOD |
Kodiak Sciences Inc.
|
1,361,000 | $51,881,320 | |
| 3 | RVMD |
Revolution Medicines, Inc.
|
500,000 | $48,625,000 | |
| 4 | KYMR |
Kymera Therapeutics, Inc.
|
329,100 | $27,410,739 | |
| 5 | CELC |
Celcuity Inc.
|
225,000 | $25,681,500 | |
| 6 | SRZN |
Surrozen, Inc./DE
|
766,318 | $22,322,843 | |
| 7 | ABVX |
Abivax S.A.
|
200,000 | $22,270,000 | |
| 8 | TERN |
Terns Pharmaceuticals, Inc.
|
375,000 | $19,770,000 |
All Filings in URGN
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $8,990,000 | 500,000 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $11,710,000 | 500,000 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $11,471,250 | 575,000 | Shares | Sole | 2026-02-17 | |
| 2025-06-30 | $7,877,500 | 575,000 | Shares | Sole | 2026-02-17 | |
| No filing history on record for this holder in this stock. | ||||||